Liquidia owes $380.7 million and will stop promoting YUTREPIA for PH-ILD. Keeping PAH sales uninterrupted and ending 6 lawsuits, with the company expecting to pay without new financing, makes the news favorable overall.
This lets Liquidia spend more time on YUTREPIA sales and new treatments instead of court fights. The cost is substantial, and the company will stop promoting YUTREPIA for PH-ILD after a court found patent infringement. Still, YUTREPIA remains available for PAH, and Liquidia says its cash and sales can cover the payments without new financing.
United Therapeutics is set to receive $380.7 million, and the settlement ends 6 disputes. Liquidia can still sell YUTREPIA for PAH, but the payment and end to the legal fights favor United Therapeutics.
Follow Liquidia Corporation (LQDA) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for LQDA